Bexagliflozin Patent Expiration
Bexagliflozin is Used for improving glycemic control in adults with type 2 diabetes. It was first introduced by Theracosbio Llc
Bexagliflozin Patents
Given below is the list of patents protecting Bexagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Brenzavvy | US8987323 | Crystalline form of benzylbenzene SGLT2 inhibitor | May 14, 2032 | Theracosbio |
| Brenzavvy | US10533032 | Crystalline form of benzylbenzene SGLT2 inhibitor | Jul 03, 2031 | Theracosbio |
| Brenzavvy | US10981942 | Crystalline form of benzylbenzene SGLT2 inhibitor | Jun 13, 2031 | Theracosbio |
| Brenzavvy | US7838499 | Benzylbenzene derivatives and methods of use | Jan 30, 2029 | Theracosbio |
| Brenzavvy | US8106021 | Benzylbenzene derivatives and methods of use | Aug 22, 2028 | Theracosbio |
| Brenzavvy | US8802637 | Benzylbenzene derivatives and methods of use | Aug 22, 2028 | Theracosbio |
About Veterinary Bexagliflozin
Bexagliflozin is used in a drug marketed by 1 company: Elanco Us Inc.
Other drugs containing Bexagliflozin are: Bexacat .
Veterinary Bexagliflozin Patents
Given below is the list of patents protecting Bexagliflozin, along with the drug name that holds that patent and the company owning that drug.
Bexagliflozin's Family Patents
